Molecular Targeting Technologies, Inc. (MTTI) is a Pennsylvania-based biotechnology company primarily focused on the development of small molecules for the molecular imaging of cardiovascular diseases and cancer. We have licensed a number of proprietary molecules that allow us to target glioma, prostate and pancreatic cancer. MTTI is also building a research reagents business for an immediate revenue stream and currently offers a range of innovative flourescence based products and bead based products for in vitro and in vivo research applications.
Mission:
Molecular Targeting Technologies, Inc. is committed to being a leading biotechnology company dedicated to translating novel technologies into tomorrow's medicine. In addition to developing agents for molecular imaging of cardiovascular diseases and cancer, MTTI is also advancing recombinant oral rabies vaccines for wildlife and other novel vaccines for various human infectious diseases.
Molecular Targeting Technologies Inc.